Comprehensive molecular characterization of treatment-free remission and molecular relapse in chronic myeloid leukemia patients: the EURO-SKI Biomarker Study

S. Rinaldetti, M. Chepeleva, A. Hedblom, C. Sticht, M. Muciek, P. Panayiotidis, J. Richter, U. Olsson-Strömberg, D. Nowak, V. Nowak, P. Ljungman, N. von Bubnoff, K. Lotfi, L. Stenke, T. H. Brümmendorf, H. Hjorth-Hansen, T. Gedde-Dahl, W. Majeed, A. Burchert, P. V. Nazarov, E. Felde, I. Tarnopolscaia, C. Hoelting, A. Fabarius, W.-K. Hofmann, F.-X. Mahon, S. Saussele, M. Pfirrmann · 2026

Read Comprehensive molecular characterization of treatment-free remission and molecular relapse in chronic myeloid leukemia patients: the EURO-SKI Biomarker Study by S. Rinaldetti, M. Chepeleva, A. Hedblom, C. Sticht, M. Muciek, P. Panayiotidis, J. Richter, U. Olsson-Strömberg, D. Nowak, V. Nowak, P. Ljungman, N. von Bubnoff, K. Lotfi, L. Stenke, T. H. Brümmendorf, H. Hjorth-Hansen, T. Gedde-Dahl, W. Majeed, A. Burchert, P. V. Nazarov, E. Felde, I. Tarnopolscaia, C. Hoelting, A. Fabarius, W.-K. Hofmann, F.-X. Mahon, S. Saussele, M. Pfirrmann (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13421316.txt.

Description

S. Rinaldetti leads a large international team reporting, in 2026, molecular findings from the EURO-SKI trial, which tested whether people with chronic myeloid leukaemia can safely stop their kinase inhibitor drugs. Many patients stay in remission off treatment, yet the biology separating them from those who relapse is poorly understood.

The team profiled gene activity in blood cells from 240 patients on their final day of drug intake, with healthy controls and untreated patients for comparison. Patients who stayed in remission showed active blood-forming gene programmes and healthy-style communication between innate and adaptive immune cells, a pattern lost in relapsers. A threshold in one gene, FLT3, also separated groups with different relapse risk. The authors suggest reinforcing these mechanisms could widen treatment-free remission.

Catalog record

CREATORS. Rinaldetti, M. Chepeleva, A. Hedblom, C. Sticht, M. Muciek, P. Panayiotidis, J. Richter, U. Olsson-Strömberg, D. Nowak, V. Nowak, P. Ljungman, N. von Bubnoff, K. Lotfi, L. Stenke, T. H. Brümmendorf, H. Hjorth-Hansen, T. Gedde-Dahl, W. Majeed, A. Burchert, P. V. Nazarov, E. Felde, I. Tarnopolscaia, C. Hoelting, A. Fabarius, W.-K. Hofmann, F.-X. Mahon, S. Saussele, M. Pfirrmann
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE44509
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13421316

Browse the full library · About the Tower of Babel